Mauro Barbosa ArrudaI; Lamartine Daniel AguiarIII; Silvio Romero de Barros MarquesIII; Luiz Rafael Pereira CavalcantiI; Michel Pompeu B. O. SáI
ABSTRACTIntroduction: This study aims to test the effect of phenytoin as an inhibitor of the process of dystrophic calcification in bovine pericardium and porcine leaflets implanted in the subcutaneous tissue of rats.
GA = Glutaraldehyde
Ig = Immunoglobulin
L = Control porcine aortic leaflets group
LF = Study porcine aortic leaflets group
P = Control bovine pericardium group
PF = Study bovine pericardium group
Calcification is a major cause of glutaraldehyde (GA)-fixed primary xenogeneic materials failure, mainly in children, leading to a high rate of reintervention[1-3]. The process and mechanism of calcification progression involving biological tissues in surgical practice is not yet fully understood. The process of calcification is related to the preservative used, due to its cytotoxic action, mechanical stress suffered by the heterograft, and host-related factors such as age, renal failure, and immune response[4-6].
GA is undoubtedly the preservative of choice in the treatment of biomaterials. Nevertheless, the main commercially used preservatives are related to the promotion of dystrophic calcification by changes in collagen structure, amino acids extraction, presence of phospholipids that attract calcium ions, and the existence of cavities and gaps in the treated tissue produced by tissue fixation and cellular degradation.
In an attempt to minimize these effects and increase the viability of xenogeneic grafts, several physical and chemical means have been associated after GA conservation, without consistent long-term results.
Phenytoin is an anticonvulsant drug synthetized in 1908. However, its non-sedative anticonvulsant properties were identified only in 1936[8,9]. Although its mechanism of action is not fully understood yet, it is proven to promote changes in calcium metabolism and activity in dystrophic calcification by its antivitamin D action.
This study aims to test the effectiveness of phenytoin as an inhibitor of the process of dystrophic calcification in porcine and bovine pericardium segments, preserved by GA and fixed by formaldehyde, implanted in the subcutaneous tissue of rats.
All samples of bovine pericardium and porcine aortic leaflets used were commercial products from Braile Biomédica (São José do Rio Preto, São Paulo, Brazil). Fresh biomaterials were selected from healthy animals immediately after slaughter and rinsed several times with 0,9% sodium chloride.
The surrounding connective tissue was thoroughly removed. Each biomaterial was preserved by treatment with GA 0,65% (0.1 M HEPES buffer, pH 7.4, at room temperature, with two changes on the 2nd and 7th day) for 21 days. The biomaterial was thoroughly rinsed three times for 20 minutes and stored in alcohol solution (mixture of 1,2-octanediol, phenoxyethanol and 2,4-hexadienoic acid [1%] and ethanol [20%]).
Eighty four-week-old male Wistar rats (100 g) received subcutaneous implants and were divided into two groups with forty rats each. Whereas the P group received a subcutaneous bovine pericardium implant, the L group received porcine leaflets implants. These two groups were subdivided again into study groups PF and LF (receiving phenytoin; each one with 20 rats) and control groups P and L (not receiving phenytoin; each one with 20 rats).
Subcutaneous Implantation Technique
All procedures were in accordance with the rules of the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, National Academy of Sciences, Washington, D.C., 1996), respected the ethical principles on animal experimentation of the Brazilian College of Animal Experimentation (or COBEA), and were duly approved by the Ethical Committee on Animal Experimentation (or CEAA), Universidade Federal de Pernambuco.
The rats were anesthetized with 10% chloral hydrate at 0.4 mL dose per 100 g of body weight and the paravertebral region was shaved. A 1.0-cm long incision was made in the skin, dividing the subcutaneous tissue enough to allow the introduction and accommodation of 1 cm2 of biomaterial samples (Figure 1). After implantation, the animals were grouped in five per standard cage, where they were kept in daily observation, following the previously established feeding and medication program. Samples were explanted on postoperative day 90, divided into two parts, and then rinsed with 0.9% sodium chloride. One part was fixed in 10% neutral buffered formalin for histological studies, and another was dried at 60° C for calcium analysis (Figure 2).
The phenytoin dosage was calculated to be five times the recommended dose of the drug for pediatric patients. The daily dose was estimated to range from 10 to 12.5 mg, equivalent to a dose of 50 mg/kg of body weight (the average weight of rats at 90 days was 250 g). The drug was added to the diet of the PF and LF groups and the mice received the drug until the day of the tissue extraction - completing 90 days of dosage.
For histological study, the parts were dehydrated in increasing concentrations of ethanol, diaphanized in xylene, and included in paraffin. Cuts were made four-micron thick and stained with Mayer’s hematoxylin-eosin and von Kossa’s method for minerals (Figure 3).
Radiologic Analysis of Graft Calcification
After fixation with 10% formaldehyde solution, the grafts were submitted to analysis of calcification through mammography (a very sensitive radiological method). General Electric - Senographe DMR mammography device was used.
The level of calcification in radiological studies was divided into: (N) normal or equal to the fixed graft; (+) focal calcification, (++) segmental calcification, and (+++) intense calcification.
Concentration of Calcium in the Grafts
After removal, the grafts were kept in 10% formaldehyde solution for 24 hours and then freeze-dried. After freeze-drying, the samples were immersed in a 6N HCl solution (at a rate of 3 mL of solution to 3 mg of freeze-dried tissue) and then hydrolyzed in a microwave system for model hydrolysis (MDS 2000 CEMCorp., Matthews, North Carolina, United States of America) for 45 minutes. After hydrolysis, the samples were diluted in a 5% 3N HCl solution. The calcium content of each sample was determined by atomic absorption spectrophotometry (AA-250Plus, PerkinElmer Inc., Norwalk, Connecticut, United States of America) and was expressed in micrograms per milligrams of dry tissue weight.
For statistical analysis of the qualitative variables, the Fisher-Freeman-Halton exact test was performed, and the data were transferred to InStat/MDR Software. For quantitative variables analysis, the Student's t-test was performed. The results were considered statistically significant when P<0.05.
The evaluation by optical microscopy showed intense inflammatory reaction, with presence of lymphocytes, histiocytes, and plasma cells in all studied groups (Figure 4). There was a statistically significant difference regarding the decrease in calcification between the groups in the optical microscopy evaluation, despite a 5% reduction of calcification in PL and LF groups (Figure 5).
Radiologic studies with mammography (Figure 6) revealed a statistically significant difference between the groups treated with and without phenytoin (not only regarding the bovine pericardium but also the porcine leaflets) (Figure 7).
In this study, calcium concentrations measured by atomic absorption spectrophotometry were lower in PF and LF groups, which used phenytoin as an inhibitor of the calcification process up to 90 days after implantation. Among P and L groups, which did not received phenytoin, and PF and LF, receiving phenytoin as an anticalcifying treatment, there was no significant difference in calcium concentration (Figure 8).
Dystrophic calcification of biomaterials and implanted bioprostheses can keep an intimate relationship with physiological calcification in bone formation[11,12]. The mineral deposit is basically the same in both processes. A deposit of hydroxyapatite crystals occurs initially in the matrix and, after exposure of these crystals to extracellular fluid, forms calcium crystals and later attracts the arrival of connective tissue, particularly collagen. These crystals become niche nurseries for the accumulation of more calcium crystals. Increased deposition of calcium crystals in active medullary formation depends on the availability of calcium and orthophosphate in extracellular fluid, and possibly the presence of collagen, which can be changed or delayed by the presence of natural mineralization inhibitors, such as proteoglycans, osteocalcin, phosphoproteins, and β-2-glycoprotein[11,13].
Aortic porcine leaflets and bovine pericardium tissue are most commonly used in the manufacture of grafts for heart defects, fixed to intracardiac bioprostheses and valve replacements, being the ones chosen in this study for their routine use in current surgical procedures[14,15].
The hypothesis that GA is one of the factors responsible for the process of calcification led researchers to develop process modifications and conservation studies, adding presumed mineralizing or inhibitory substances until replacement of fixatives.
Vitamin D and the parathyroid hormones play a crucial role in regulating calcium metabolism, activating calcium-binding proteins, increasing their serum level, and acting on their intestinal absorption. Low serum vitamin D levels reduce available calcium levels for bone formation and, therefore, reduce bone mass. On the other hand, increased vitamin D serum levels can cause calcification of various other organs, but with minimal effect on the bones themselves.
The increase in vitamin D metabolism can occur in young animals and in some human diseases, such as renal failure, infectious processes, and as an immune response of the host in the case of children and young people. Age-dependent aspects of vitamin D metabolism may be linked to age-dependent aspects in heterografts and calcification of bioprostheses. Vitamin D is a stimulant for osteocalcin biosynthesis that is closely linked to the process of physiological and pathological calcification, and can interact to promote age-dependent calcification in GA-fixed tissue, through the action of osteocalcin.
Phenytoin is a potent non-sedative anticonvulsant drug recommended by the American Epilepsy Society Guidelines to treat seizures unresponsive to benzodiazepines[7,21]. Its anticonvulsants properties are thought to stem from its activity in sodium and calcium channels[7,8]. Barnhart described that prolonged use of phenytoin may cause side effects such as osteomalacia, hypocalcemia, hyperphosphatemia, and increased parathyroid hormone concentration. Phenytoin appears to exert an immunosuppressive effect on humans, reducing lymphocyte synthesis and proportional reduction in cells. It can cause a reduction in serum levels of immunoglobulin (Ig) G, IgM, IgA, IgE and decreased ability to demonstrate delayed hypersensitivity reactions, although these findings are dose- and time-dependent.
Phenytoin’s antivitamin D effect occurs through increased induction of hepatic microsomal level of vitamin D catabolism and its metabolic effects and biological assets through a change in hepatic conversion of vitamin D (calciferol to 25-hydroxycalciferol). Liao et al. showed the effectiveness of phenytoin in inhibiting rat myocardial calcification and subcutaneously implanted bovine pericardium segments, when subjected to a special diet that enhances calcification, including myocardium.
The inhibitory action of calcification by phenytoin was to test phenytoin’s antivitamin D action in delaying the calcification process of xenomaterials implanted in subcutaneous tissue of rats. In our study, the phenytoin daily dose was set to be five times greater than human pediatric dosage. This addition was done on purpose, since the mouse metabolism is higher/faster than the human metabolism, it would enable a more effective assessment of phenytoin action, assuming that increasing the dose could have a greater action on calcium metabolism.
The presence of fibrosis in the pathway, frequently found in histological studies (Figures 1 and 2), is related to the histological type of fixed xenograft used. The bovine pericardium is rich in type I collagen and the porcine aortic leaflets are rich in type III collagen, occurring more frequently in bovine pericardium than in porcine aortic leaflets.
The evaluation by optical microscopy showed intense inflammatory reaction, with presence of lymphocytes, histiocytes, and plasma cells in all studied groups. The ability of GA to form covalent connections with proteins decreasing its antigenicity does not preclude the presence of intense inflammatory reaction in the literature reports, possibly because of its residual action. These findings differ from those found by Liao et al., who suggested that the inflammatory reaction between the grafts and the GA-fixed host could be controlled with the use of phenytoin. There was a statistically significant difference regarding the decrease of calcification between the groups in the optical microscopy evaluation, despite a 5% reduction of calcification in PL and LF groups.
In this study, calcium concentrations measured by atomic absorption spectrophotometry were lower in PF and LF groups, which used phenytoin as an inhibitor of the calcification process up to 90 days after implantation. Some authors reported that the calcium concentration of GA-fixed grafts is progressive and related to the time of implant[11,12,24], occurring more frequently at 45 days after implantation and being more dramatic at 90 days.
Among P and L groups, which did not received phenytoin, and PF and LF groups, receiving phenytoin as anticalcifying treatment, there was no significant difference in calcium concentration. These findings agree with those of Jorge-Herrero et al., suggesting that bovine pericardium tissues and porcine aortic leaflets are not prone to the calcification process. Both of which are used to make bioprostheses, with a greater tendency to use of bioprostheses made with bovine pericardium compared to those manufactured with porcine aortic leaflets.
The results found in this study (decreased incidence of macroscopic changes in consistency and staining, lower incidence of focal calcification and lower inflammatory reaction, lower incidence of calcification seen in radiological studies with mammography equipment, as well as by the lower calcium concentration, as measured by atomic absorption spectrophotometry, in PF and LF groups, which used phenytoin as an anticalcifying treatment) suggests that the antivitamin D action of phenytoin inhibited the process of dystrophic calcification.
1. Chandy T, Vasudev SC, Rao GH. Changes in pericardial calcification due to antiplatelet agents: in vitro studies. Artif Organs. 1998;22(8):666-71. doi:10.1046/j.1525-1594.1998.06028.x.
2. Milano A, Bortolotti U, Talenti E, Valfrè C, Arbustini E, Valente M, et al. Calcific degeneration as the main cause of porcine bioprosthetic valve failure. Am J Cardiol. 1984;53(8):1066-70. doi:10.1016/0002-9149(84)90638-6.
3. Schoen FJ, Maranto AR, Webb CL, Levy RJ. Cuspal components in bioprosthetic valve calcification: Elucidation and modification. In: Bodnar (editor). Surgery for heart valve disease. London: ICR Publishers; 1990. p. 679-88.
4. Deiwick M, Glasmacher B, Pettenazzo E, Hammel D, Castellón W, Thiene G, et al. Primary tissue failure of bioprostheses: new evidence from in vitro tests. Thorac Cardiovasc Surg. 2001;49(2):78-83. doi:10.1055/s-2001-11711. [MedLine]
5. David TE, Ivanov J. Is degenerative calcification of the native aortic valve similar to calcification of bioprosthetic heart valves? J Thorac Cardiovasc Surg. 2003;126(4):939-41. doi:10.1016/s0022-5223(03)00731-1.
6. Schoen FJ. Pathologic findings in explanted clinical bioprosthetic valves fabricated from photooxidized bovine pericardium. J Heart Valve Dis. 1998;7(2):174-9.
7. Carpentier A, Lemaigre G, Robert L, Carpentier S, Dubost C. Biological factors affecting long-term results of valvular heterografts. J Thorac Cardiovasc Surg. 1969;58(4):467-83.
8. Hall EA, Wheless JW, Phelps SJ. Status epilepticus: the slow and agonizing death of phenytoin. J Pediatr Pharmacol Ther. 2020;25(1):4-6. doi:10.5863/1551-6776-25.1.4. [MedLine]
9. Keppel Hesselink JM, Kopsky DJ. Phenytoin: 80 years young, from epilepsy to breast cancer, a remarkable molecule with multiple modes of action. J Neurol. 2017;264(8):1617-21. doi:10.1007/s00415-017-8391-5. [MedLine]
10. Liao K, Seifter E, Factor SM, Yellin EL, Frater RW. Diphenylhydantoin inhibits calcification of bovine pericardial implants and myocardium: a preliminary study. J Surg Res. 1992;53(4):349-56. doi:10.1016/0022-4804(92)90060-d.
11. Schoen FJ, Tsao JW, Levy RJ. Calcification of bovine pericardium used in cardiac valve bioprostheses. Implications for the mechanisms of bioprosthetic tissue mineralization. Am J Pathol. 1986;123(1):134-45.
12. Levy RJ, Schoen FJ, Levy JT, Nelson AC, Howard SL, Oshry LJ. Biologic determinants of dystrophic calcification and osteocalcin deposition in glutaraldehyde-preserved porcine aortic valve leaflets implanted subcutaneously in rats. Am J Pathol. 1983;113(2):143-55.
13. Anderson HC. Mechanism of mineral formation in bone. Lab Invest. 1989;60(3):320-30.
14. Vasudev SC, Chandy T, Sharma CP, Mohanty M, Umasankar PR. Effects of double cross-linking technique on the enzymatic degradation and calcification of bovine pericardia. J Biomater Appl. 2000;14(3):273-95. doi:10.1177/088532820001400305.
15. Aupècle B, Serraf A, Belli E, Mohammadi S, Lacour-Gayet F, Fornes P, et al. Intermediate follow-up of a composite stentless porcine valved conduit of bovine pericardium in the pulmonary circulation. Ann Thorac Surg. 2002;74(1):127-32. doi:10.1016/s0003-4975(02)03639-1.
16. Barnhart ER (editor). Physician's desk reference. 45th ed. Oradell (NJ): Medical Economics Data; 1991.
17. Hahn TJ. Bone complications of anticonvulsants. Drugs. 1976;12(3):201-11. doi:10.2165/00003495-197612030-00003.
18. Kent SP, Vawter GF, Dowben RM, Benson RE. Hypervitaminosis D in monkeys; a clinical and pathologic study. Am J Pathol. 1958;34(1):37-59. [MedLine]
19. DeLuca HF, Zierold C. Mechanisms and functions of vitamin D. Nutr Rev. 1998;56(2 Pt 2):S4-10; discussion S 54-75. doi:10.1111/j.1753-4887.1998.tb01686.x.
20. Price PA, Baukol SA. 1,25-Dihydroxyvitamin D3 increases synthesis of the vitamin K-dependent bone protein by osteosarcoma cells. J Biol Chem. 1980;255(24):11660-3.
21. Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American epilepsy society. Epilepsy Curr. 2016;16(1):48-61. doi:10.5698/1535-7597-16.1.48. [MedLine]
22. Pettenazzo E, Deiwick M, Thiene G, Molin G, Glasmacher B, Martignago F, et al. Dynamic in vitro calcification of bioprosthetic porcine valves: evidence of apatite crystallization. J Thorac Cardiovasc Surg. 2001;121(3):500-9. doi:10.1067/mtc.2001.112464.
23. Chang Y, Tsai CC, Liang HC, Sung HW. In vivo evaluation of cellular and acellular bovine pericardia fixed with a naturally occurring crosslinking agent (genipin). Biomaterials. 2002;23(12):2447-57. doi:10.1016/s0142-9612(01)00379-9.
24. Jorge-Herrero E, Fernández P, Turnay J, Olmo N, Calero P, García R, et al. Influence of different chemical cross-linking treatments on the properties of bovine pericardium and collagen. Biomaterials. 1999;20(6):539-45. doi:10.1016/s0142-9612(98)90205-8.
25. Braile DM. Valvular prosthesis of bovine pericardium development and clinical application in mitral position. . São Paulo: Escola Paulista de Medicina; 1990.
No financial support.
No conflict of interest.
Authors' roles & responsibilities
MBAF Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published
LDA Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published
SRBM Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published
LRPC Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published
MPBOS Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published
Article receive on Tuesday, May 19, 2020
Article accepted on Thursday, October 1, 2020